Axa releases largest single-tranche CDO

Axa Investment Managers this week issued a €1.3 billion managed synthetic collateralised debt obligation (CDO), called Aria CDO 1, the largest single-tranche deal to date.

The deal, arranged by JP Morgan Chase, was issued in five currencies – Swiss francs, sterling, dollars, euros and yen. It offers investors the possibility to receive fixed, floating and inflation-linked coupons, across a range of rated tranches and with bullet maturities of either five or seven years.

Aria closes this Friday and has 25 different tranches, referencing a portfolio of some 140 corporate names. It was designed with the intention of attracting a broad investor base across Europe, following the success of the Overture deal, released by Axa last November, and also arranged by JP Morgan Chase. The Overture deal hit the headlines last year as the largest CDO released into the European market and the first to be distributed on a syndicated basis, rather than being underwritten by a single investment bank.

Like Overture, Aria was globally syndicated by a team of banks: Royal Bank of Scotland in the UK, Gulf International Bank in the Middle East, Mizuho Securities in Japan, Natexis Banques Populaires in France and the Korean Development Bank. This, said the arrangers, has allowed the deal to gain greater global access to investors, with around 60 different investors in 15 countries. And also, with more institutions analysing the underlying bonds, investors can be more confident of their credit quality than with other CDOs.

The arrangers said Aria was released partly to meet the excess demand for the Overture CDO, which had seen some of the more senior tranches up to nine times over-subscribed.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here